Basic Information
GALLIUM CITRATE (Ga 67) INJECTION 37 MBq/ml
INJECTION
Regulatory Information
SIN09913P
July 28, 1998
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
XV09HX01
Company Information
Active Ingredients
Strength: 37 MBq/ml at ART
Detailed Information
Contraindications
**Contraindications** Gallium Citrate (Ga-67) Injection is contraindicated in lactating mothers unless the child is formula-fed for a period of at least three weeks after the injection. No other contraindications are known.
Indication Information
**Indications** Scintigraphy with gallium-67 is indicated in: - the clinical evaluation of patients suspected of neoplastic diseases, notably Hodgkin’s disease, other malignant lymphomas, soft tissue sarcomas and most bronchogenic carcinomas. - the localisation of metastases of malignant melanomas. - the differentiation of hepatoma and liver metastases, and pleural and peritoneal mesotheliomas. - determining the extent of involvement of malignancy. - the follow-up of tumour therapy and screening for recurrent tumour. - the localisation of focal inflammatory lesions and the evaluation of fever of unknown origin.